Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel

Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies....

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 36; no. 1; p. 178
Main Authors Yang, Zhan, Chen, Jin-Suo, Wen, Jin-Kun, Gao, Hai-Tao, Zheng, Bin, Qu, Chang-Bao, Liu, Kai-Long, Zhang, Man-Li, Gu, Jun-Fei, Li, Jing-Dong, Zhang, Yan-Ping, Li, Wei, Wang, Xiao-Lu, Zhang, Yong
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 08.12.2017
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies. miR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth. miR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3'-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo. Silencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC.
AbstractList Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies. miR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth. miR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3'-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo. Silencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC.
Abstract Background Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies. Methods miR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth. Results miR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3′-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo. Conclusions Silencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC.
BACKGROUNDDocetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to docetaxel-induced apoptosis. Hence, there is an urgent need to identify mechanisms of docetaxel chemoresistance and to develop new combination therapies.METHODSmiR-193a-5p level was evaluated by qPCR in prostate tissues and cell lines, and its expression in the tissues was also examined by in situ hybridization. PC cell line (PC3 cell) was transfected with miR-193a-5p mimic or its inhibitor, and then cell apoptosis and the expression of its downstream genes Bach2 and HO-1 were detected by TUNEL staining and Western blotting. Luciferase reporter assay was used to detect the effect of miR-193a-5p and Bach2 on HO-1 expression. Xenograft animal model was used to test the effect of miR-193a-5p and docetaxel on PC3 xenograft growth.RESULTSmiR-193a-5p was upregulated in PC tissues and PC cell lines, with significant suppression of PC3 cell apoptosis induced by oxidative stress. Mechanistically, miR-193a-5p suppressed the expression of Bach2, a repressor of the HO-1 gene, by directly targeting the Bach2 mRNA 3'-UTR. Docetaxel treatment modestly decreased Bach2 expression and increased HO-1 level in PC3 cells, whereas a modest increase of HO-1 facilitated docetaxel-induced apoptosis. Notably, docetaxel-induced miR-193a-5p upregulation, which in turn inhibits Bach2 expression and thus relieves Bach2 repression of HO-1 expression, partly counteracted docetaxel-induced apoptosis, as evidenced by the increased Bcl-2 and decreased Bax expression. Accordingly, silencing of miR-193a-5p enhanced sensitization of PC3 cells to docetaxel-induced apoptosis. Finally, depletion of miR-193a-5p significantly reduced PC xenograft growth in vivo.CONCLUSIONSSilencing of miR-193a-5p or blockade of the miR-193a-5p-Bach2-HO-1 pathway may be a novel therapeutic approach for castration-resistant PC.
ArticleNumber 178
Audience Academic
Author Gu, Jun-Fei
Zheng, Bin
Li, Jing-Dong
Chen, Jin-Suo
Li, Wei
Yang, Zhan
Wang, Xiao-Lu
Gao, Hai-Tao
Zhang, Man-Li
Liu, Kai-Long
Qu, Chang-Bao
Zhang, Yan-Ping
Wen, Jin-Kun
Zhang, Yong
Author_xml – sequence: 1
  givenname: Zhan
  surname: Yang
  fullname: Yang, Zhan
  organization: Department of Science and Technology, The Second Hospital of Hebei Medical University, 215 Heping W Rd, Shijiazhuang, 050000, China
– sequence: 2
  givenname: Jin-Suo
  surname: Chen
  fullname: Chen, Jin-Suo
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 3
  givenname: Jin-Kun
  surname: Wen
  fullname: Wen, Jin-Kun
  organization: Department of Biochemistry and Molecular Biology, Ministry of Education of China, Hebei Medical University, No. 361 Zhongshan E Rd, Shijiazhuang, 050017, China
– sequence: 4
  givenname: Hai-Tao
  surname: Gao
  fullname: Gao, Hai-Tao
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 5
  givenname: Bin
  surname: Zheng
  fullname: Zheng, Bin
  organization: Department of Biochemistry and Molecular Biology, Ministry of Education of China, Hebei Medical University, No. 361 Zhongshan E Rd, Shijiazhuang, 050017, China
– sequence: 6
  givenname: Chang-Bao
  surname: Qu
  fullname: Qu, Chang-Bao
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 7
  givenname: Kai-Long
  surname: Liu
  fullname: Liu, Kai-Long
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 8
  givenname: Man-Li
  surname: Zhang
  fullname: Zhang, Man-Li
  organization: Department of Emergency Medicine, The second hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China
– sequence: 9
  givenname: Jun-Fei
  surname: Gu
  fullname: Gu, Jun-Fei
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 10
  givenname: Jing-Dong
  surname: Li
  fullname: Li, Jing-Dong
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 11
  givenname: Yan-Ping
  surname: Zhang
  fullname: Zhang, Yan-Ping
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 12
  givenname: Wei
  surname: Li
  fullname: Li, Wei
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 13
  givenname: Xiao-Lu
  surname: Wang
  fullname: Wang, Xiao-Lu
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China
– sequence: 14
  givenname: Yong
  surname: Zhang
  fullname: Zhang, Yong
  email: zhangyong89@sina.com
  organization: Department of Urology, The Second Hospital of Hebei Medical University, 215 Heping West Road, Shijiazhuang, 050000, China. zhangyong89@sina.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29216925$$D View this record in MEDLINE/PubMed
BookMark eNptkttq3DAQhk1JaA7tA_SmGAqlN0411sm6KYTQQyBQ6OGyCK082lWwpa2lDc3bV66TsAtFFxKab37m8J9VRyEGrKpXQC4AOvE-ASVMNARkQwRTDX1WnYLkolFKiKO990l1ltItIQIUqOfVSataEKrlp9Wv737AYH1Y19HVo__WgKKm4dvaBzuhSZjqvMHabnCMCUPy2d_5fD_T2ymmbHIJmmBxqi0OQ6Fj3UeL2fzB4UV17MyQ8OXDfV79_PTxx9WX5ubr5-ury5vGilblRkk0QDklyoK0qgfCemWplJJJJCvqROes6Cn2LVrXcQKKM4W8M9w5rig9r64X3T6aW72d_Gimex2N1_8-4rTWZsreDqjdyrWKGVwBMEaYXXFqiORlHsBch33R-rBobXerEXuLIU9mOBA9jAS_0et4p7mcReZi3j0ITPH3DlPWo0_zbEzAuEsalCwdcNVBQd8s6NqU0nxwsSjaGdeXnAkqqRCqUBf_ocrpcfS2WMKVHR4mvN1L2KAZ8ibFYZd9DOkQhAW0ZZVpQvfUJhA9W0wvFtPFYnq2mJ7be70_n6eMR0_Rv768zFw
CitedBy_id crossref_primary_10_1096_fj_201900537R
crossref_primary_10_1097_MD_0000000000034998
crossref_primary_10_1111_joa_13612
crossref_primary_10_1186_s12964_018_0270_x
crossref_primary_10_1080_21655979_2022_2068756
crossref_primary_10_1111_iju_15043
crossref_primary_10_1016_j_ncrna_2022_02_002
crossref_primary_10_1186_s12935_020_1098_1
crossref_primary_10_3390_ijms21020404
crossref_primary_10_1177_15353702231191199
crossref_primary_10_1158_1535_7163_MCT_19_0051
crossref_primary_10_3389_fcell_2021_737812
crossref_primary_10_1038_s41598_023_45250_9
crossref_primary_10_1111_jcmm_16202
crossref_primary_10_1038_s41374_022_00736_4
crossref_primary_10_18632_aging_202271
crossref_primary_10_3390_foods13060960
crossref_primary_10_3390_genes12081206
crossref_primary_10_3389_fonc_2021_710525
crossref_primary_10_3390_biom13020266
crossref_primary_10_3390_ijms21176183
crossref_primary_10_1111_acel_13430
crossref_primary_10_3390_cancers13030550
crossref_primary_10_1186_s12935_022_02475_4
crossref_primary_10_1002_cam4_3726
crossref_primary_10_1186_s13046_020_01814_5
crossref_primary_10_7717_peerj_7451
crossref_primary_10_1111_febs_16681
crossref_primary_10_1002_jcb_27906
crossref_primary_10_3892_mmr_2022_12878
crossref_primary_10_1186_s12935_021_02020_9
crossref_primary_10_1186_s13072_023_00483_w
crossref_primary_10_1042_BSR20190150
crossref_primary_10_1096_fj_202300980R
crossref_primary_10_1007_s10555_024_10168_9
crossref_primary_10_1038_s41388_018_0602_8
crossref_primary_10_1134_S0006297922050030
crossref_primary_10_1186_s43556_020_00004_1
crossref_primary_10_1002_jcb_29374
crossref_primary_10_1002_jcb_29451
crossref_primary_10_2174_1871520622666220601093452
crossref_primary_10_3389_fimmu_2023_1135753
crossref_primary_10_1080_15384047_2019_1599659
crossref_primary_10_2176_jns_nmc_2023_0200
crossref_primary_10_1007_s11033_022_07763_w
crossref_primary_10_1002_jcp_29724
crossref_primary_10_1038_s41419_021_03854_x
crossref_primary_10_3390_antiox12061217
crossref_primary_10_1016_j_intimp_2020_107355
crossref_primary_10_1111_andr_13086
crossref_primary_10_1016_j_reprotox_2022_04_003
crossref_primary_10_1186_s40709_021_00151_8
crossref_primary_10_3390_cimb45050273
crossref_primary_10_2147_COPD_S298465
crossref_primary_10_3892_mmr_2021_12221
crossref_primary_10_1038_s41419_019_1943_0
crossref_primary_10_3389_fonc_2019_01535
crossref_primary_10_3390_antiox10050789
crossref_primary_10_2147_CMAR_S232757
crossref_primary_10_2174_1874609816666230816152744
crossref_primary_10_1016_j_bbcan_2020_188481
crossref_primary_10_1016_j_redox_2018_04_020
crossref_primary_10_3390_molecules24122335
crossref_primary_10_3389_fonc_2020_00850
crossref_primary_10_1096_fj_202200673RRR
crossref_primary_10_1038_s12276_021_00623_w
Cites_doi 10.1038/onc.2012.360
10.1016/j.cell.2004.12.035
10.1002/path.2855
10.1111/j.1442-2042.2009.02341.x
10.2174/138161208784246225
10.1016/j.biocel.2006.03.013
10.1016/j.bbrc.2004.01.118
10.1158/0008-5472.CAN-16-2355
10.18632/oncotarget.12684
10.1172/JCI82884
10.1016/j.yexcr.2016.03.001
10.1038/sj.onc.1209632
10.1097/00001622-200011000-00006
10.1074/jbc.M707773200
10.1158/1078-0432.CCR-06-0147
10.1158/0008-5472.CAN-14-0795
10.1038/onc.2013.574
10.1016/j.bcp.2013.12.009
10.1158/0008-5472.CAN-09-0419
10.1016/j.ajpath.2012.08.011
10.1186/1471-2407-14-308
10.1152/physrev.00011.2005
10.1093/emboj/20.11.2835
10.1016/j.freeradbiomed.2011.09.014
10.1186/gb-2010-11-8-r90
10.1097/CEJ.0b013e32834a7f0c
10.7150/jca.15620
10.1158/1535-7163.MCT-06-0272
10.1038/aps.2010.48
10.1158/0008-5472.CAN-10-1447
10.1038/sj.bjc.6604081
10.1016/j.molonc.2013.10.001
10.1080/01635581.2014.868909
10.18632/oncotarget.10950
10.1006/bbrc.1997.6943
10.1111/j.1365-2559.2006.02412.x
10.1002/pros.20824
10.1016/S0929-6646(08)60100-X
10.18632/oncotarget.8624
10.1074/jbc.M203929200
10.7150/jca.6394
10.1038/sj.onc.1203716
10.1016/j.eururo.2016.05.002
10.1517/14796694.1.1.91
10.1186/1476-4598-13-234
10.1182/blood-2005-12-040972
10.1186/1471-2407-11-221
10.1038/nm.3247
10.1002/jcb.20794
ContentType Journal Article
Copyright COPYRIGHT 2017 BioMed Central Ltd.
The Author(s). 2017
Copyright_xml – notice: COPYRIGHT 2017 BioMed Central Ltd.
– notice: The Author(s). 2017
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1186/s13046-017-0649-3
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 178
ExternalDocumentID oai_doaj_org_article_fbf294aeb114404cb53a07521614f8ed
A546373669
10_1186_s13046_017_0649_3
29216925
Genre Journal Article
GrantInformation_xml – fundername: The National Natural Science Foundation of China
  grantid: 81672555
– fundername: The National Natural Science Foundation of China
  grantid: 81600237
– fundername: ;
  grantid: 81672555; 81600237
GroupedDBID ---
-5E
-5G
-A0
-BR
0R~
29K
2WC
3V.
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFO
ACGFS
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
AAYXX
CITATION
AFGXO
ABVAZ
AFNRJ
7X8
5PM
ID FETCH-LOGICAL-c629t-97ea135309c17c9d104d9c377747e0b3f68fc6d3ed2ecf85019549e58a5ff5933
IEDL.DBID RPM
ISSN 1756-9966
0392-9078
IngestDate Tue Oct 22 15:12:18 EDT 2024
Tue Sep 17 21:15:21 EDT 2024
Fri Oct 25 06:50:08 EDT 2024
Thu Feb 22 23:30:41 EST 2024
Tue Nov 12 22:53:44 EST 2024
Tue Aug 20 22:12:35 EDT 2024
Fri Sep 13 05:35:14 EDT 2024
Wed Oct 16 01:00:27 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Bach2
HO-1
miR-193a-5p
Prostate cancer
Chemoresistance
Docetaxel
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c629t-97ea135309c17c9d104d9c377747e0b3f68fc6d3ed2ecf85019549e58a5ff5933
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721613/
PMID 29216925
PQID 1975015981
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_fbf294aeb114404cb53a07521614f8ed
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5721613
proquest_miscellaneous_1975015981
gale_infotracmisc_A546373669
gale_infotracacademiconefile_A546373669
gale_healthsolutions_A546373669
crossref_primary_10_1186_s13046_017_0649_3
pubmed_primary_29216925
PublicationCentury 2000
PublicationDate 2017-12-08
PublicationDateYYYYMMDD 2017-12-08
PublicationDate_xml – month: 12
  year: 2017
  text: 2017-12-08
  day: 08
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2017
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References E Francini (649_CR5) 2016; 70
M Pennati (649_CR11) 2014; 87
J Busserolles (649_CR45) 2006; 38
KH Pulkkinen (649_CR35) 2011; 51
J Zhou (649_CR15) 2016; 7
XB Shi (649_CR10) 2015; 75
JM Grad (649_CR49) 2000; 12
S Reagan-Shaw (649_CR51) 2008; 68
YB Wetherill (649_CR1) 2006; 5
MA Alaoui-Jamali (649_CR44) 2009; 69
A Matsumoto (649_CR4) 2009; 16
T Kirkegaard (649_CR32) 2006; 48
P Sacca (649_CR47) 2007; 97
S Zhang (649_CR24) 2014; 66
R Roychoudhuri (649_CR52) 2016; 126
SG Patterson (649_CR37) 2006; 25
R Sullivan (649_CR20) 2008; 14
M Puhr (649_CR6) 2012; 181
IE Eder (649_CR3) 2005; 1
S Rajput (649_CR43) 2012; 21
BA Walter (649_CR33) 2013; 4
Z Yang (649_CR28) 1852; 2015
S Sasaki (649_CR36) 2000; 19
SS Lee (649_CR46) 2008; 107
GH Shi (649_CR12) 2010; 31
C Yoshida (649_CR25) 2007; 109
G Ploussard (649_CR39) 2010; 70
K Ogawa (649_CR22) 2001; 20
E Chun (649_CR48) 2004; 315
T Kietzmann (649_CR23) 2003; 278
S Swaminathan (649_CR26) 2013; 19
Y Yang (649_CR13) 2013; 32
Y Li (649_CR19) 2011; 224
SW Ryter (649_CR18) 2006; 86
C Huang (649_CR42) 2016; 7
H Deng (649_CR17) 2014; 13
T Yoshino (649_CR50) 2006; 12
SM Dehm (649_CR2) 2006; 99
QF Ye (649_CR7) 2012; 3
Y Xie (649_CR38) 2008; 283
BP Lewis (649_CR30) 2005; 120
JY Seo (649_CR29) 2017; 2017
L Heinemann (649_CR34) 2011; 11
C Jacques (649_CR16) 2016; 7
Q Cao (649_CR40) 2016; 7
D Wen (649_CR9) 2017; 77
SK Leivonen (649_CR41) 2014; 8
CJ Nie (649_CR8) 2016; 342
K Itoh (649_CR21) 1997; 236
T Yu (649_CR14) 2015; 34
X Wang (649_CR27) 2014; 14
D Betel (649_CR31) 2010; 11
References_xml – volume: 32
  start-page: 3432
  year: 2013
  ident: 649_CR13
  publication-title: Oncogene
  doi: 10.1038/onc.2012.360
  contributor:
    fullname: Y Yang
– volume: 120
  start-page: 15
  year: 2005
  ident: 649_CR30
  publication-title: Cell
  doi: 10.1016/j.cell.2004.12.035
  contributor:
    fullname: BP Lewis
– volume: 224
  start-page: 90
  year: 2011
  ident: 649_CR19
  publication-title: J Pathol
  doi: 10.1002/path.2855
  contributor:
    fullname: Y Li
– volume: 16
  start-page: 687
  year: 2009
  ident: 649_CR4
  publication-title: Int J Urol
  doi: 10.1111/j.1442-2042.2009.02341.x
  contributor:
    fullname: A Matsumoto
– volume: 3
  start-page: 879
  year: 2012
  ident: 649_CR7
  publication-title: Oncol Lett
  contributor:
    fullname: QF Ye
– volume: 14
  start-page: 1113
  year: 2008
  ident: 649_CR20
  publication-title: Curr Pharm Des
  doi: 10.2174/138161208784246225
  contributor:
    fullname: R Sullivan
– volume: 38
  start-page: 1510
  year: 2006
  ident: 649_CR45
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2006.03.013
  contributor:
    fullname: J Busserolles
– volume: 315
  start-page: 771
  year: 2004
  ident: 649_CR48
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2004.01.118
  contributor:
    fullname: E Chun
– volume: 77
  start-page: 3244
  year: 2017
  ident: 649_CR9
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2355
  contributor:
    fullname: D Wen
– volume: 7
  start-page: 77468
  year: 2016
  ident: 649_CR40
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12684
  contributor:
    fullname: Q Cao
– volume: 126
  start-page: 599
  year: 2016
  ident: 649_CR52
  publication-title: J Clin Invest
  doi: 10.1172/JCI82884
  contributor:
    fullname: R Roychoudhuri
– volume: 342
  start-page: 20
  year: 2016
  ident: 649_CR8
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2016.03.001
  contributor:
    fullname: CJ Nie
– volume: 25
  start-page: 6113
  year: 2006
  ident: 649_CR37
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209632
  contributor:
    fullname: SG Patterson
– volume: 12
  start-page: 543
  year: 2000
  ident: 649_CR49
  publication-title: Curr Opin Oncol
  doi: 10.1097/00001622-200011000-00006
  contributor:
    fullname: JM Grad
– volume: 2015
  start-page: 1477
  year: 1852
  ident: 649_CR28
  publication-title: Biochim Biophys Acta
  contributor:
    fullname: Z Yang
– volume: 283
  start-page: 3349
  year: 2008
  ident: 649_CR38
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M707773200
  contributor:
    fullname: Y Xie
– volume: 12
  start-page: 6116
  year: 2006
  ident: 649_CR50
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-0147
  contributor:
    fullname: T Yoshino
– volume: 2017
  start-page: 5906189
  year: 2017
  ident: 649_CR29
  publication-title: Mediat Inflamm
  contributor:
    fullname: JY Seo
– volume: 75
  start-page: 5309
  year: 2015
  ident: 649_CR10
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-0795
  contributor:
    fullname: XB Shi
– volume: 34
  start-page: 413
  year: 2015
  ident: 649_CR14
  publication-title: Oncogene
  doi: 10.1038/onc.2013.574
  contributor:
    fullname: T Yu
– volume: 87
  start-page: 579
  year: 2014
  ident: 649_CR11
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2013.12.009
  contributor:
    fullname: M Pennati
– volume: 69
  start-page: 8017
  year: 2009
  ident: 649_CR44
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-0419
  contributor:
    fullname: MA Alaoui-Jamali
– volume: 181
  start-page: 2188
  year: 2012
  ident: 649_CR6
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2012.08.011
  contributor:
    fullname: M Puhr
– volume: 14
  start-page: 308
  year: 2014
  ident: 649_CR27
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-14-308
  contributor:
    fullname: X Wang
– volume: 86
  start-page: 583
  year: 2006
  ident: 649_CR18
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00011.2005
  contributor:
    fullname: SW Ryter
– volume: 20
  start-page: 2835
  year: 2001
  ident: 649_CR22
  publication-title: EMBO J
  doi: 10.1093/emboj/20.11.2835
  contributor:
    fullname: K Ogawa
– volume: 51
  start-page: 2124
  year: 2011
  ident: 649_CR35
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2011.09.014
  contributor:
    fullname: KH Pulkkinen
– volume: 11
  start-page: R90
  year: 2010
  ident: 649_CR31
  publication-title: Genome Biol
  doi: 10.1186/gb-2010-11-8-r90
  contributor:
    fullname: D Betel
– volume: 21
  start-page: 205
  year: 2012
  ident: 649_CR43
  publication-title: Eur J Cancer Prev
  doi: 10.1097/CEJ.0b013e32834a7f0c
  contributor:
    fullname: S Rajput
– volume: 7
  start-page: 1740
  year: 2016
  ident: 649_CR15
  publication-title: J Cancer
  doi: 10.7150/jca.15620
  contributor:
    fullname: J Zhou
– volume: 5
  start-page: 3181
  year: 2006
  ident: 649_CR1
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-06-0272
  contributor:
    fullname: YB Wetherill
– volume: 31
  start-page: 867
  year: 2010
  ident: 649_CR12
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/aps.2010.48
  contributor:
    fullname: GH Shi
– volume: 70
  start-page: 9253
  year: 2010
  ident: 649_CR39
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-1447
  contributor:
    fullname: G Ploussard
– volume: 97
  start-page: 1683
  year: 2007
  ident: 649_CR47
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604081
  contributor:
    fullname: P Sacca
– volume: 8
  start-page: 93
  year: 2014
  ident: 649_CR41
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2013.10.001
  contributor:
    fullname: SK Leivonen
– volume: 66
  start-page: 315
  year: 2014
  ident: 649_CR24
  publication-title: Nutr Cancer
  doi: 10.1080/01635581.2014.868909
  contributor:
    fullname: S Zhang
– volume: 7
  start-page: 54503
  year: 2016
  ident: 649_CR16
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10950
  contributor:
    fullname: C Jacques
– volume: 236
  start-page: 313
  year: 1997
  ident: 649_CR21
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1997.6943
  contributor:
    fullname: K Itoh
– volume: 48
  start-page: 787
  year: 2006
  ident: 649_CR32
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2006.02412.x
  contributor:
    fullname: T Kirkegaard
– volume: 68
  start-page: 1624
  year: 2008
  ident: 649_CR51
  publication-title: Prostate
  doi: 10.1002/pros.20824
  contributor:
    fullname: S Reagan-Shaw
– volume: 107
  start-page: 355
  year: 2008
  ident: 649_CR46
  publication-title: J Formos Med Assoc
  doi: 10.1016/S0929-6646(08)60100-X
  contributor:
    fullname: SS Lee
– volume: 7
  start-page: 35874
  year: 2016
  ident: 649_CR42
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8624
  contributor:
    fullname: C Huang
– volume: 278
  start-page: 17927
  year: 2003
  ident: 649_CR23
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M203929200
  contributor:
    fullname: T Kietzmann
– volume: 4
  start-page: 350
  year: 2013
  ident: 649_CR33
  publication-title: J Cancer
  doi: 10.7150/jca.6394
  contributor:
    fullname: BA Walter
– volume: 19
  start-page: 3739
  year: 2000
  ident: 649_CR36
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1203716
  contributor:
    fullname: S Sasaki
– volume: 70
  start-page: 410
  year: 2016
  ident: 649_CR5
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.05.002
  contributor:
    fullname: E Francini
– volume: 1
  start-page: 93
  year: 2005
  ident: 649_CR3
  publication-title: Future Oncol
  doi: 10.1517/14796694.1.1.91
  contributor:
    fullname: IE Eder
– volume: 13
  start-page: 234
  year: 2014
  ident: 649_CR17
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-13-234
  contributor:
    fullname: H Deng
– volume: 109
  start-page: 1211
  year: 2007
  ident: 649_CR25
  publication-title: Blood
  doi: 10.1182/blood-2005-12-040972
  contributor:
    fullname: C Yoshida
– volume: 11
  start-page: 221
  year: 2011
  ident: 649_CR34
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-11-221
  contributor:
    fullname: L Heinemann
– volume: 19
  start-page: 1014
  year: 2013
  ident: 649_CR26
  publication-title: Nat Med
  doi: 10.1038/nm.3247
  contributor:
    fullname: S Swaminathan
– volume: 99
  start-page: 333
  year: 2006
  ident: 649_CR2
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.20794
  contributor:
    fullname: SM Dehm
SSID ssj0061919
Score 2.4868321
Snippet Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to...
BACKGROUNDDocetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC) cells to...
Abstract Background Docetaxel-based chemotherapy failure in advanced prostate carcinoma has partly been attributed to the resistance of prostate cancer (PC)...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 178
SubjectTerms Apoptosis
Bach2
Cancer
Chemoresistance
Chemotherapy
Docetaxel
Genes
HO-1
miR-193a-5p
Prostate cancer
RNA
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_Sg3gRtX5MrTWCIAihm8nk4x1rsZRCPaiFXiRkMgku2Jmls4X--X1vZnbZwYMXr5s3kLzPX_Z9hLGP1gUAq7WoFQRRmbwQtSylyFChPtmAfpMahS-_mfOr6uJaX-889UU1YeN44JFxx7nOJVQBXQqlIatYaxUwzJWIVKrsUjN43wVsLlOjD8ZbgYQphymdOe4lJQAFeWQMwSDULAoNw_r_dsk7MWleL7kTgM6esacTcuQn446fs0epfcEeX0658X3268eSGogwFPEu85vld4GoKQi94suWoGGfeo5oj6OUbrqe6tbHhyOIekW9H4g6eSQluOX0dz5Sd7zB8LYO9-nPS3Z19vXn6bmYHk8Q0ZSwFmBToDctFhCljdDgtauBqCzCPZsWtcrG5WgalZoyxew0NQ5WkLQLOmcNSr1ie23XpjeMR4MfJCNTRCyQkoVE-USao4jRX2Uo2OcNM_1qnJHhh7uFM37kvEfOe-K8VwX7QuzeEtJ46-EHFLqfhO7_JfSCvSdh-bFXdGuk_oSG-1tlDO7p00BBZooyi2HqNsAT0cCrGeXhjBLNK86WP2wUwtMS1aS1qbvrvUQdRzAFThbs9agg21OVgHuFUhfMzlRnduz5Srv8PUz31jROSaqD_8Gnt-xJSUpP5TfukO2tb-_SOwRR6_posJcHciAXVg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3di9QwEA_nCeKL-G311AiCIEQ3TZN0HkRO8TiE80FduBcJaZrowl27bvfg_O-dabvLFs_XZro0mZnMb3a-GHtpSw9gtRaVAi8Kk2aikrkUCQqUJ-vx3qRC4ZMv5nhefD7Vp3tsM95qPMDuSteO5knNV2dvLn__eY8K_65X-NK87SSF9wTdt2hgQahr7HpeoKNOmXzFNqiAroKEMbB55WvUGBhyaYDmZu9Yqb6Z_79X9o7NmuZT7hioo9vs1ogs-eEgCnfYXmzushsnY-z8HvvxbUEFRmiqeJv4-eKrQFTlhV7yRUPQsYsdRzTIkYvnbUd57cNgCaJeUm0IolIeSEhWnP7uR-qW12j-1v4ynt1n86NP3z8ei3G4gggmh7UAGz3NvJhBkDZAjW5ZDUFZhIM2ziqVTJmCqVWs8xhSqamwsICoS69T0qDUA7bftE18xHgw-EI0MgbECjFaiBRvpD6LiA5Ugoy93hymWw49NFzve5TGDUxwyARHTHAqYx_ouLeE1P66f9CufrpRm1yqUg6FRztDsekiVFp5xD7IO1mkMtYZe07MckMt6VaJ3SE1_7fKGPymVz0FCRbyLPixGgF3RA2xJpQHE0pUvzBZfrERCEdLlLPWxPaicxJ1AMEWlDJjDwcB2e5qI2cZsxPRmWx7utIsfvXdvzW1W5Lq8X9_8wm7mZNQU85NecD216uL-BSR07p61uvDXyYdEa4
  priority: 102
  providerName: Scholars Portal
Title Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel
URI https://www.ncbi.nlm.nih.gov/pubmed/29216925
https://search.proquest.com/docview/1975015981
https://pubmed.ncbi.nlm.nih.gov/PMC5721613
https://doaj.org/article/fbf294aeb114404cb53a07521614f8ed
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZtB2MvY_d56zINBoOBmtiybo9NaSmDlJKtEAZD2LLUBRo7xCn05_ccX0LM3vbiB-vYWD6fdD5J50LIV6UzY5QQLOcmY6kME5bHScyCSQFPKoN5EwOFZ1fy8ib9sRCLAyL6WJjGad_ly5PybnVSLv82vpXrlRv3fmLj69mZwIwzMR8fkkN4Yb9Eb6dfWBA01TwmYPgZrPx0d5QZazmuYzwHZDgxgyU2DIvoJAbeZbBS9p5datL3_ztJ71mpoQflnkm6eEGed1ySnrbf_JIc-PIVeTrrTstfkz8_lxhSBMaJVoGulnMGPCpjYk2XJZLF2tcU-B8Fva2qGj3Z21ISKL3GaBDgodQhLDYUN_hBuqIFGLxt9uDv3pCbi_NfZ5esK6fAnEzMlhnlM6xyMTEuVs4UsBArjOMKCKDyk5wHqYOTBfdF4l3QAkMJU-OFzkQIwnD-lhyVVenfE-okPOBl7B2wA--V8XjCiJkVgQ_wYCLyvf-Zdt1mzbDNakNL2yrBghIsKsHyiEzxd-8EMeF1c6Pa3NpO7TbkITFpBpYFT6NTlwueAdtBHKRB-yIin1FZto0e3Q1be4rp_hWXEr7pWyOBAxd05rIu_gB6hCmwBpLHA0kYcG7Q_KUHhMUm9FIrfXVf2xhQD_TK6Dgi71qA7HrV4ywiagCdQbeHLQD_Jt93B_cP__3kR_IsQdCjF44-Jkfbzb3_BFxqm49gBC3UiDyZnl9dz0fNjgRcZ6mG63z6e9SMrUcx3x8G
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,31732,33757,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_nCeqL-HlWTy-CIAi5bZsmaR7Pw2PV20P0Du5FQpomWrhtl-0e-Oc7049li2--NtPSdGYyv-l8EfJO5VZrJQQruLYskyFmRZImLOgM5ElZODexUHhxIedX2Zdrcb1HxFgL0yXtu6I6rm-Wx3X1u8utXC3dbMwTm31bnArsOJPw2R1yF_Q1zkYnvT-AwSXo5nnEYPoZ-H75EMxMcjlrE4wEMjyawRZrhmN0Ug1P0zgre8cydQ38_z2md-zUNIdyxyidPSIPBzRJT_q3fkz2fP2E3FsM8fKn5OePCouKwDzRJtBl9Z0BkrJMrGhVI1xsfUsBAVLg3LJpMZe9HyaB1CusBwEkSh0KxpriL36gbmgJJm9j__ibZ-Tq7NPl6ZwNAxWYk6neMK28xTkXsXaJcroEV6zUjiuAgMrHBQ8yD06W3JepdyEXWEyYaS9yK0IQmvPnZL9uav-CUCfhBi8T7wAfeK-0xxgj9lYERMCDjsiH8WOaVd83w3T-Ri5NzwQDTDDIBMMj8hE_95YQW153F5r1LzMw3oQipDqzYFswHp25QnALeAclIQu5LyNyhMwyff3oVnHNCTb8V1xKeKf3HQWqLvDM2aECAXaETbAmlIcTSlA5N1l-OwqEwSXMU6t9c9uaBOQeAJbOk4gc9AKy3dUoZxFRE9GZbHu6AgrQdfweBP7lf995RO7PLxfn5vzzxddX5EGKCoA5Ofkh2d-sb_1rQFab4k2nR38BoSYc_Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEBZtCqEvpXedpI0KhUJB8SFblh7TtEt6bAhtA3kpQpal1pC1zXoD_fmd8bGs6VtfrbGxPDOabzwXIW9yaZTKs4wVXBmWCh-xIk5i5lUK8pQbODexUHh5Ic6v0s_X2fXOqK8-ad8W1Ul9szqpq999bmW7suGUJxZeLs8y7DgT87AtfXiX3AOdjcTkqA-HMLgF_UyPCMw_A_9PjgHNWIqwizEayPB4BnusGI7SSRQ8UeG87B3r1Dfx__eo3rFV8zzKHcO0eEgejIiSng5v_ojccfVjsr8cY-ZPyM_vFRYWgYmijaer6hsDNGVY1tKqRsjYuY4CCqTAvVXTYT77MFACqVusCQE0Si0Kx5rib36gbmgJZm9j_ribp-Rq8fHH2TkbhyowKxK1YSp3BmddRMrGuVUluGOlsjwHGJi7qOBeSG9FyV2ZOOtlhgWFqXKZNJn3meL8Gdmrm9q9INQKuMGJ2FnACM7lymGcEfsrAirgXgXk3fQxdTv0ztC9zyGFHpiggQkamaB5QN7j594SYtvr_kKz_qVH5mtf-ESlBuwLxqRTW2TcAOZBaUi9dGVAjpFZeqgh3SqvPsWm_zkXAt7pbU-B6gs8s2asQoAdYSOsGeXRjBLUzs6WX08CoXEJc9Vq19x2OgbZB5ClZByQ54OAbHc1yVlA8pnozLY9XwEl6Lt-j0J_8N93HpP9yw8L_fXTxZdDcj9B-ce0HHlE9jbrW_cSwNWmeNWr0V_CTR4Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Silencing+of+miR-193a-5p+increases+the+chemosensitivity+of+prostate+cancer+cells+to+docetaxel&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Yang%2C+Zhan&rft.au=Chen%2C+Jin-Suo&rft.au=Wen%2C+Jin-Kun&rft.au=Gao%2C+Hai-Tao&rft.date=2017-12-08&rft.eissn=1756-9966&rft.volume=36&rft.issue=1&rft.spage=178&rft_id=info:doi/10.1186%2Fs13046-017-0649-3&rft_id=info%3Apmid%2F29216925&rft.externalDocID=29216925
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon